Background: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases. Objective: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH. Subjects and methods: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing. Results: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements. Conclusions: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in !10% of syndromic CH patients.
Introduction
The proliferation and terminal differentiation of the anterior pituitary gland are strongly influenced by the precise spatial and temporal expression of transcription factors (1, 2, 3) . Mutations in these transcription factors result in various types of congenital hypopituitarism (CH), ranging from isolated growth hormone deficiency (IGHD) to multiple pituitary hormone deficiency (MPHD) (1, 2, 3) . 165 MPHD patients from the international GENHYPOPIT network. These results imply the rarity of pathological abnormalities in the previously known genes in CH patients and strongly suggest that other causative genes for CH remain to be identified in most patients.
Several cases of CH with submicroscopic chromosomal rearrangements, such as 20p11 deletions and 22q12.3q13.3 duplication, whose definitive causative genes responsible for CH are not fully captured, have been reported (6, 7, 8) . These patients were syndromic and showed extra pituitary clinical spectra, including dysmorphic faces, midline defects, and intellectual disability. Because most cases of CH are sporadic, we hypothesized that de novo chromosomal rearrangements could be a certain fraction of the molecular mechanisms participating in the etiology, especially in syndromic cases. Therefore, we decided to perform a genome-wide screening for submicroscopic anomalies in our syndromic CH cohort to determine the role of copy number variations (CNVs) in the etiology of CH, and to identify new candidate loci and thus novel candidate genes for CH.
Subjects and methods

Subjects
This study population consisted of 88 patients with GH-treated CH. The inclusion criteria were as follows: i) severe GH deficiency (GH peak !3 ng/ml) confirmed by hypoglycemic provocation tests and ii) anterior pituitary hypoplasia as detected by a brain magnetic resonance imaging (MRI). Of the 88 patients, 30 were syndromic (CH with extra-pituitary abnormalities such as midline defects, intellectual disability, and cardiac defects), whereas 58 were non-syndromic. The details of 30 syndromic patients are summarized in Table 1 . In all the patients, mutations in POU1F1, PROP1, HESX1, LHX3, LHX4, OTX2, SOX2, SOX3, and GLI2 have been excluded by PCR-based sequencing (4) . Gene copy number aberrations in POU1F1, PROP1, HESX1, LHX3, and LHX4 were also excluded by multiplex ligation-dependent probe amplification (MLPA) analyses (4) . Approval for this study was obtained from the Institutional Review Board of Keio University School of Medicine. We obtained written informed consent for molecular studies from the patient or the patient's parents.
Endocrinological investigations
Hormonal assays were performed using several commercial RIA kits, and normal values for each center were taken into account. The results of biochemical investigations at diagnosis were recorded including basal free thyroxine (fT 4 ), thyroid-stimulating hormone (TSH), cortisol, adrenocorticotropin (ACTH) levels, and their peaks in response to pituitary stimulation tests. The patients were evaluated for serum GH level after two consecutive classical provocative tests (with arginine or insulin). GH peaks, 6 ng/ml after stimuli, support a diagnosis of GHD. GH peaks, 3 ng/ml by hypoglycemic provocation test, define severe GHD. A diagnosis of TSH deficiency was made if serum fT 4 concentration was under the normal level (fT 4 , 1.0 ng/dl) with inadequate low to normal serum TSH concentration. Cortisol peaks, 17 mg/dl by hypoglycemic provocation tests, define ACTH deficiency. Folliclestimulating hormone (FSH)-luteinizing hormone (LH) deficiency was diagnosed on the basis of delayed or absent pubertal development at the age of 16 years and inadequate increase in serum FSH and LH in response to LH-releasing hormone.
Of the 88 patients, on the basis of hormonal deficiencies, 13 were determined to have IGHD, whereas 75 had MPHD (Supplementary Table 1 , see section on supplementary data given at the end of this article).
Imaging investigations
MRI included T1 and T2-weighted, high-resolution pituitary imaging through the hypothalamo-pituitary-axis (T1 sagittal 3-mm slices, T1 and T2 coronal 3-mm slices). Details noted included the size of the anterior pituitary, position of the posterior pituitary signal, presence and morphology of the optic nerves, optic chiasm, pituitary stalk, septum pellucidum, and corpus callosum.
Results of the MRI scans were available in all patients with IGHD and MPHD. Details regarding the structural abnormalities of the hypothalamo-pituitary-axis on neuroimaging in the probands are given in Supplementary Table 2 , see section on supplementary data given at the end of this article.
PAX6 mutation screening
For all the 88 patients, we analyzed all coding exons and flanking introns of PAX6 by PCR-based sequencing. For detailed protein sequence information, see EMBL database accession numbers ENSP00000368418 (PAX6). We screened for deletion/duplication involving PAX6 by MLPA analyses (SALSA MLPA KIT P219; MRC-Holland, Amsterdam, The Netherlands). We tested for any detected sequence variations against 150 Japanese control subjects.
Functional studies on the novel PAX6 mutation (p.N116S)
The details of the experimental procedures are described in Supplementary methods, see section on supplementary data given at the end of this article. In brief, PAX6 cDNA was cloned into pCMV-myc and pEGFP-N1 (Clontech) to generate PAX6 expression vectors. We introduced the mutation by site-directed mutagenesis using the Prime STAR Mutagenesis Basal kit (TaKaRa, Otsu, Japan). The primer pairs, forward (F) and reverse (R), used for mutagenesis were as follows: N116S (F)-5 0 -AACGATAGCA-
Transactivation assay was performed using P6CON luciferase reporter vector, which was constructed by inserting the six copies of PAX6 consensus binding elements, and dual-luciferase reporter assay system (Promega) on COS1 and GH3 cells. For subcellular localization analyses, we visualized and photographed COS1 cells transfected with GFP-tagged PAX6.
For western blotting analyses, we harvested COS1 cells 
Crystal structure modeling
The crystal structure of the PAX6 paired domain (protein data bank ID 6PAX; http://www.rcsb.org/pdb/) was used as a reference WT structure for modeling the structure of p.N116S PAX6 by using the PyMOL Molecular Graphics System (http://www.pymol.org).
Results
CGH array screening
Among the 30 syndromic CH patients, we identified one heterozygous deletion, which was of estimated minimum extent 308 kb, extending from bp 31 474 276 to bp 31 783 119 on chromosome 11q13 (NCBI Build 37/hg 19) (Fig. 1A) . Maximum size was 311 kb, from bp 31 471 923 to bp 31 785 385. The deletion included two genes (ELP4 and IMMP1L) and PAX6 putative enhancer region, with the coding region of PAX6 being unaffected, in one patient with IGHD, cleft palate, and optic disc cupping. The deletion of the PAX6 putative enhancer, or other deletions encompassing the one we identified, was not registered as frequent, non-pathogenic CNVs in existing database, including the database of genomic variants, DECIPHER, and UCSC. To confirm the deletion, fluorescence in situ hybridization (FISH) was performed on the metaphase slides from peripheral blood lymphocytes using the RP11-151O13 clones (Fig. 1A) . Parental analysis revealed that the clinically normal father possessed the deletion in somatic mosaicism (number of cells with PAX6 haploinsufficiency was eight, out of 20 counted cells), confirmed by FISH, whereas the mother did not. Second, we also identified one heterozygous 6.5-Mb deletion encompassing OTX2 (Fig. 1B) in a MPHD patient with bilateral anophthalmia, dysmorphic facies, severe developmental delay, and a patent ductus arteriosus. No other syndromic CH patients had pathological CNVs.
PAX6 mutation screening
We identified one novel heterozygous PAX6 mutation, namely p.N116S (Fig. 1C) . The p.N116 in PAX6 is an evolutionarily highly conserved amino acid located in the showed that the propositus and his clinically normal mother carried the same heterozygous PAX6 p.N116S mutation. (Fig. 1C) . The p.N116S was not detected in any of the 150 healthy controls and was absent from extant database, including dbSNP, the 1000 Genomes Project, Exome Variant Server, and NHLBI Exome Sequencing Project. We detected no gross or exon-level deletions/ duplications on performing the MLPA analyses.
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Clinical phenotypes of the mutation carriers Pedigree 1: PAX6 enhancer deletion " The propositus was a 6-year-old Japanese boy, who was born at 37 weeks of gestation after an uncomplicated pregnancy and delivery (Fig. 1A) . (Fig. 2B) , and he died at the age of 1 year. The older sister did not have a short stature. Hormonal data of the father, harboring the deletion in somatic mosaicism, was not evaluated.
Pedigree 2: OTX2 deletion " The propositus was a 6-yearold Japanese boy, who was born at 40 weeks of gestation after an uncomplicated pregnancy and delivery (Fig. 1B) .
The patient was the third child of non-consanguineous healthy parents. His older brother and sister were clinically normal. At birth, his length was 51.0 cm (1.0 S.D.) and weight 3.05 kg (0.1 S.D.). A constellation of malformations was noticed, including bilateral anophthalmia, and small and uplifted earlobes with very small external auditory canals. The testes were undescended, the scrotum small, and the foreskin hypoplastic. Echocardiogram revealed a patent ductus arteriosus, which was surgically corrected at 1 month of age. At the age of 1 year, he was diagnosed with central hypothyroidism with a low fT 4 Table 4 , see section on supplementary data given at the end of this article). The brain MRI exhibited anterior pituitary hypoplasia, visible but thin stalk, and EPP (Fig. 2C ). Replacement therapy with thyroxine and recombinant human GH was started at the ages of 1 and 3 years respectively. No other family members were available for genetic studies or evaluation of hormonal data.
Pedigree 3: PAX6 p.N116S " The propositus was a 15-year-old Japanese male, who was born at 40 weeks of gestation after an uncomplicated pregnancy and delivery (Fig. 1C) Table 6 , see section on supplementary data given at the end of this article).
Functional studies
Both in COS1 and GH3 cells, WT PAX6 stimulated the transcription of the P6CON reporter in a dose-dependent manner. The p.N116S retained partial activity without any dominant negative effect (Fig. 3A) . The p.N116S mutant localized to the nucleus (Fig. 3B) . The western blot analysis showed that the expression of the p.N116S was comparable with that of the WT (Fig. 3C) . The WT PAX6 showed specific binding to the oligonucleotide elements,
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which was competed for by an excess amount of cold competitors (200 times). The p.N116S bound with similar efficiency to the WT PAX6 (Fig. 3D) .
Crystal structure modeling
The p.N116S was predicted to lose the hydrogen bond between N116 and T113 (Fig. 3E) .
Discussion
This study describes the first series of CH patients to be screened for chromosomal rearrangements with highresolution oligonucleotide microarrays. Overall, this study identified two different CNVs with a possible role in the etiology of CH in two patients among 30 syndromic CH patients (6.6%). Thus, the causes of CH remain elusive in most patients, and further studies are required to understand the pathogenesis of CH. PAX6 is a well-known regulator of eye development, and its heterozygous mutations in humans cause congenital eye anomalies such as aniridia, foveal hypoplasia, optic-nerve malformations, and Peters' anomaly. Kioussi et al. (9) showed that PAX6 is an early dorsal marker of early anterior pituitary gland, and its expression controls the established boundaries of somatotrope, lactotrope, and thyrotrope cell types. Dorsal expression of PAX6 is essential for establishing a sharp boundary between dorsal and ventral cell types, and the absence of PAX6 leads to a marked increase in the thyrotrope cell lineage, whereas the somatotrope and lactotrope cell lineage changes are very much diminished (9) . These data strongly support our findings that PAX6 mutations are associated with CH.
Recently two papers have been published, showing that PAX6 mutations may be associated with impaired pituitary function (10, 11) . Hergott et al. reported data on detailed pituitary studies using the stimulation testing of five PAX6 mutation carriers (10) . In this paper, they found no clear pituitary deficiencies other than subtle corticotrope deficiency. Shimo et al. (11) reported one case of PAX6 mutation with subtle hypogonadotropic hypogonadism and borderline GH deficiency. However, this particular case is unconvincing because the subject was obese (which blunts GH response to GH stimulation testing), had normal adult stature of 165 cm, normal menses and pregnancies. Therefore, we showed, for the first time, that heterozygous PAX6 mutations are associated with definite CH patients with or without ocular malformation, and the frequency of PAX6 mutations in CH was 2.3%. To date, more than 350 mutations or variants in PAX6 have been reported (12) , and almost all were found in the heterozygous state. Although extremely rare, at least four patients harboring biallelic mutations in PAX6 have been reported (13, 14, 15) . Three patients were stillborn or died in early infancy with severe CNS anomalies, but one long surviving patient among them showed MPHD and anterior pituitary hypoplasia (13) , further supporting a role for PAX6 in the pituitary development in human.
In pedigree 1, we identified a heterozygous 310 kb deletion of the downstream flanking region of PAX6 in an IGHD patient with cleft palate and bilateral optic disc cupping. The known control that PAX6 exerts over the temporospatial expression of Sonic hedhehog (SHH) (16) , the critical importance of PAX6 on pituitary development through SHH (9), and the critical importance of SHH on palate development (17) strongly support the argument for PAX6 defects being pathogenic events responsible for the phenotype. Previously, several authors described submicroscopic deletions downstream of PAX6, with the coding region of PAX6 being unaffected (18, 19, 20, 21, 22) . Davis et al. (18) identified a 1.3 Mb deletion, including six neighboring genes: ELP4, DPH4, DCDC1, DCDC5, MPPED2, and IMMP1L, localized w35 kb downstream of PAX6 in a patient with aniridia, autism, and intellectual disability. Analysis of the region with a breakpoint located 124 kb downstream of the PAX6 polyadenylation site using YAC transgenic mice, DNase I hypersensitivity mapping and reporter transgenic assays, showed the presence of several cis-regulatory elements, including a lens-specific and a retina-specific element. These elements are located within the introns of the ELP4 gene and are PAX6-specific long-range control elements (22, 23) . ELP4, which is ubiquitous but with variable expression in human tissues, acts as subunit of the RNA polymerase II elongator complex, which is a histone acetyltransferase component of the RNA polymerase II holoenzyme and is involved in transcriptional elongation (24) . IMMP1L, which is located at the mitochondrion inner membrane, catalyzes the removal of transit peptides required for the targeting of proteins from the mitochondrial matrix across the inner membrane into the inter-membrane space (25) . The deletion, we identified, includes ELP4 and IMMP1L. While deletions in the ELP4 gene have been shown to suppress PAX6 gene expression and cause aniridia (19) , implications of IMMP1L in the described phenotype are not clear. Although pituitaryspecific elements are not well studied, we believe that our findings will shed light on the role for PAX6 in the pituitary development in humans.
Wide phenotypic spectrum in PAX6 mutation carriers is noteworthy. In pedigree 1, the proband's older brother was diagnosed to have holoprosencephaly, the most common forebrain developmental anomaly in humans. Unfortunately gene analysis data for the brother were not available. However, the mosaicism of the deletion in his father strongly suggested that the most severe phenotype was due to the same deletion and the variable penetrance of PAX6 mutations. Of course, the effect of environmental factors, second hit in PAX6, or mutation in other genes for holoprosencephaly, was not excluded. In pedigree 3, the patient's mother was of normal adult height and had normal baseline hormonal levels. The p.N116S was associated with impaired transactivation without dominant-negative effects, indicating haploinsufficiency. The western blotting analysis, visualization of subcellular localization, and a DNA-binding test revealed no significant difference between the WT and p.N116S PAX6. Asn 116 is a highly conserved amino acid located in the paired domain, suggesting that substitution of Asn 116 to Ser, which is predicted to lose the hydrogen bond between N116 and T113, results in defective interactions with transcriptional cofactors. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. PAX genes may be sometimes monoallelicaly expressed and the individual factors governing such monoalleic expression are not understood. Since the found mutation is heterozygous, theoretically a favorable monoallelic expression from the correct allele in the mother might cause the lack of phenotype, and the expression from the mutated allele in the patient might cause the phenotype (26, 27, 28) . The phenotypical variation within the same pedigree could also be partly due to the impact of other genes that are important but have not been recognized in pituitary development. Of course, the possibility that p.N116S PAX6 could have no significance in vivo effect in human, and that he had a de novo mutation in some other yet-to-be-identified gene causative for CH, should also be considered.
In summary, we showed, for the first time, that heterozygous PAX6 mutations are associated with definite CH patients with or without ocular malformation. The frequency of PAX6 mutations in CH was 2.3%. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in CH in !10% of the syndromic CH patients.
